sb 202190 has been researched along with Eczema, Atopic in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kagami, S | 1 |
| Saeki, H | 1 |
| Komine, M | 1 |
| Kakinuma, T | 1 |
| Tsunemi, Y | 1 |
| Nakamura, K | 1 |
| Sasaki, K | 1 |
| Asahina, A | 1 |
| Tamaki, K | 1 |
1 other study available for sb 202190 and Eczema, Atopic
| Article | Year |
|---|---|
Interleukin-4 and interleukin-13 enhance CCL26 production in a human keratinocyte cell line, HaCaT cells.
Topics: Cell Line, Tumor; Cell Movement; Chemokine CCL26; Chemokines, CC; Culture Media, Conditioned; Dermat | 2005 |